GoAI
Get started
Tiziana Life Sciences Ltd logo

Tiziana Life Sciences Ltd

TLSA

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$1.17

+$0.03 · +2.63%

Aug 24, 11:13 AM ET

TLSA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

25

Expensive

Momentum

32

Weakening

Sentiment

53

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.

Industry
Biotechnology
Sector
Healthcare
Headquarters
GB
CEO
Ivor R. Elrifi
Listed since
Nov 20, 2018
Employees
10

Market position

Day range

Current $1.17

52-week range

Current $1.17

Open
$1.15
Previous close
$1.14
Volume
520.27K
1.22× average
Average volume
424.88K
Average daily volume
Market cap
74.45M USD
Beta
0.46
Market reference 1
50-day average
$1.098
+6.56% above average
200-day average
$1.3701
-14.60% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
84.57M USD
P/E (TTM)
-4.2×
P/B (TTM)
2.38×
P/S (TTM)
0×
EV / EBITDA
-4.65×
Earnings yield
-20.92%
Free cash flow yield
-14.60%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-35444.23%
Return on assets
-160.34%
Return on invested capital
-4159.84%

Financial health

Debt / equity
0.01×
Current ratio
0.76×

Financial statements

Income trends

Operating income

−21.13M USD-33.80%

Net income

−18.43M USD-55.37%
Income trends across reported periods−9.36M USD−19.38M USD−29.41M USD−39.43M USDOperating income, FY2021: −36.93M USDOperating income, FY2022: −17.93M USDOperating income, FY2023: −22.73M USDOperating income, FY2024: −15.79M USDOperating income, FY2025: −21.13M USDNet income, FY2021: −31.59M USDNet income, FY2022: −18.92M USDNet income, FY2023: −22.36M USDNet income, FY2024: −11.86M USDNet income, FY2025: −18.43M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −36.93M USD. Operating income FY2022 −17.93M USD. Operating income FY2023 −22.73M USD. Operating income FY2024 −15.79M USD. Operating income FY2025 −21.13M USD. Net income FY2021 −31.59M USD. Net income FY2022 −18.92M USD. Net income FY2023 −22.36M USD. Net income FY2024 −11.86M USD. Net income FY2025 −18.43M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development10.28M USD5.23M USD10.25M USD15.92M USD17.82M USD
Selling, general, and administrative—10.28M USD8.26M USD4.76M USD1.15M USD
Operating expenses21.13M USD15.79M USD22.73M USD17.93M USD36.93M USD
Interest income19K USD814K USD1.46M USD——
Interest expense18K USD6K USD12.64K USD8.6K USD237.41K USD
Depreciation and amortization234K USD124K USD121.34K USD62.68K USD190.2K USD
Operating income−21.13M USD−15.79M USD−22.73M USD−17.93M USD−36.93M USD
Net income−18.43M USD−11.86M USD−22.36M USD−18.92M USD−31.59M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.32
FY2025
Latest fiscal-year revenue
0 USD
FY2025

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.18-0.35-0.51-0.68FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend0.10.03-0.03-0.1FY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy267%
Hold133%
Sell00%
Strong sell00%

Corporate actions

Corporate action history

Stock split

Effective Oct 21, 2021

1:2

Stock split

Effective Jul 31, 2020

2,499:1,000

Stock split

Effective Oct 29, 2019

2:1

TLSA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.72

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.71

-0.28%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.55

-0.09%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$379.11

+0.08%

Sanofi logo

SNY

Sanofi

$45.6206

-0.50%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.22

-1.06%

Continue in GoAI

Research TLSA

research.disclaimer